Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD Bank of England Statistics AD Investing.com Markets AD LSEG Data AD CME Group Education
Venues & MTFs

OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial

Trade Hub UK regulation desk (2026-10-19): (RTTNews) - OSE Immunotherapeutics SA (OSE), a clinical-stage biotech company, announced topline results from the Combi-TED academic Phase 2 international… Primary source: original at Nasdaq Market Structure (nasdaq.com).

By Nasdaq Market Structure

OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial

(RTTNews) - OSE Immunotherapeutics SA (OSE), a clinical-stage biotech company, announced topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi sponsored by FoRT and evaluating Tedopi (OSE2101), in combination with either chemotherapy or anti-P

Read at source

Read also
  1. Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study
  2. Taiwan Stock Market May Open Under Water On Monday
  3. Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.
  4. Global Weather Risks Push Coffee Prices Sharply Higher
  5. Warren Buffett Warned About Stock Valuations. So Why Is Berkshire Still Buying Stocks?

Source: Nasdaq Market Structure